Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. 28/08/2026			5-day change	1st Jan Change
950.47 ^PKR	-0.52%		-3.74%	-7.04%

08-27	Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-18	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	50,359	-	-
Change	-	11.36%	-7.04%	-	-
Enterprise Value (EV)	48,650	54,175	50,359	50,359	50,359
Change	-	11.36%	-7.04%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.66x	1.47x	1.31x
EV / Revenue	-	0x	1.66x	1.47x	1.31x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.73%	5.47%	6.31%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	950.47	950.47	950.47
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	26/03/25	07/04/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.73%	182M
ELI LILLY AND COMPANY	33.44x	12.14x	24.6x	0.59%	1,047B
JOHNSON & JOHNSON	29.82x	-	-	2%	646B
ABBVIE INC.	32.61x	7.57x	15.74x	2.68%	451B
ROCHE HOLDING AG	19.99x	4.75x	11.76x	2.79%	355B
NOVARTIS AG	21.76x	5.62x	13.93x	2.85%	291B
ASTRAZENECA PLC	20.88x	4.29x	12.24x	2.06%	252B
AMGEN INC.	27.35x	7.07x	12.56x	2.33%	234B
NOVO NORDISK A/S	13.25x	4.77x	9.95x	3.83%	203B
GILEAD SCIENCES, INC.	-44.51x	6.43x	25.11x	2.26%	181B
Average	17.17x	6.58x	15.74x	2.61%	365.95B
Weighted average by Cap.	24.24x	8.07x	17.81x	1.97%